Navigation Links
Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Date:11/29/2007

CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that Dr. Matt Coffey, Chief Scientific Officer of Oncolytics, is scheduled to deliver a presentation on Wednesday, December 5, 2007 entitled "Large Scale Production Process for the Oncolytic Agent REOLYSIN(R) (Human Reovirus)" at the Informa Life Sciences' 3rd Annual Vaccine Production Conference in Cologne, Germany. The conference runs from December 4-5, 2007.
For more information about the conference, please visit

http://www.informa-ls.com/vaccines.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process presented at this conference, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's abilit
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... DUBLIN , Feb. 27, 2015 Research and Markets ... the "Global Market Report of Trypsin" report to ... Trypsin (CAS 9002-07-7) aims at providing comprehensive data on Trypsin ... Asia , North America , ... trends, pays close attention to Trypsin This report ...
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... with patients and health care advocates in the United ... Day®. Rare Disease Day is dedicated to elevating ... the special challenges faced by patients with rare diseases ... proud to stand alongside patients and caregivers representing the ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... Brings Growth Opportunities in Transplant Diagnostics, Genetic Testing ... DIEGO, April 8 Gen-Probe (Nasdaq: ... completed its acquisition of Tepnel Life Sciences, plc, ... company based in the United Kingdom, for 27.1 ...
... and Peru , expansion of ... to reduce drug development timelines for biopharmaceutical companies - PRINCETON, ... ) today announced the recent opening of new clinical development ... of the company,s Buenos Aires, Argentina office. These latest ...
... CHICAGO, April 7 The following release is ... http://www.newscom.com/cgi-bin/prnh/20090325/DC89081LOGO ... on the importance of medical science and discovery ... changes are critical to maintaining America,s leadership in ...
Cached Biology Technology:Gen-Probe Completes Acquisition of Tepnel Life Sciences 2Gen-Probe Completes Acquisition of Tepnel Life Sciences 3Gen-Probe Completes Acquisition of Tepnel Life Sciences 4Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office 2Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office 3Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for 'Best and Brightest Forum on Medical Innovation' 2
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/5/2015)... TRIANGLE PARK, N.C. , Feb. 5, 2015 /PRNewswire/ ... a specialist logistics company and has launched a new ... only Clinical Logistics Organization (CLO).  The new campaign focuses ... emphasis on patient, protocol and shipments. The ... First , aligns Marken,s priorities with its client,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken Launches New Patient-Centric Campaign 2
... Following an intense study of agricultural ecosystems near ... analysis and management of a wide range of ... of McGill University,s Department of Geography, Elena Bennett ... Peterson of the Stockholm Resilience Centre at Stockholm ...
... Gorun, PhD, associate professor of chemistry at New ... was awarded a patent today for a novel ... Perfluoroalkyl Perfluoro-Phthalocyanine Compounds" (US Patent Number 7,670,684) discloses ... new materials are comprised of organic scaffolds with ...
... 2010 In one of the most comprehensive global studies ... from the University of Rhode Island and other institutions has ... driving the success of marine reserves. "We make a ... coral, fish and other aquatic organisms," said Richard Pollnac, URI ...
Cached Biology News:Seeing the hidden services of nature 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2Scientists find community involvement, not only enforcement, drives success of marine reserves 2
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Tissue culture grade....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... The Nick Translation System is ideal ... DNA. The Nick Translation System: Provides ... labeled nucleotide incorporation Yields >10 8 ... Includes control DNA to monitor the performance ...
Biology Products: